Trigemina Secures $4,500,000 Series A Funding Round

Xconomy – Trigemina, Inc. exploits a newly discovered pathway for targeting the central nervous system, enabling vast new opportunities for treating acute and chronic pain. Proceeds for the Series A-1 round will be used to fund the completion of the Phase II TRIG-05 clinical trial evaluating the Company’s lead drug candidate, TI-001, an intranasal oxytocin therapy, for the treatment of chronic migraine.

Xconomy
June 20, 2013

See the original article

Comments are closed.